Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Cancer Lett. 2014 Oct 12;380(2):525–533. doi: 10.1016/j.canlet.2014.09.035

Table 2.

Clinical trials with Ang-2 and VEGF-axis combination therapies (active and/or recruiting).

Angiopoietin-targeted agent VEGF-targeted Agent Tumor Setting Clinical Trial
Phase I
MEDI3617 Bevacizumab Solid tumors NCT01248949
Nesvacumab (REGN910) Ziv-Aflibercept Solid tumors NCT01688960
Phase II
Trebananib Bevacizumab mCRC NCT01249521
Trebananib Bevacizumab RCC NCT01664182
Pazopanib
Sorafenib
Sunitinib
Trebananib Bevacizumab Glioblastoma NCT01609790
Trebananib Bevacizumab Metastatic breast cancer NCT00511459
Trebananib Sorafenib HCC NCT00872014
Trebananib Sunitinib RCC NCT00853372
Trebananib Sorafenib RCC NCT00467025

mCRC: metastatic colorectal cancer, RCC: renal cell carcinoma, HCC: hepatocellular carcinoma.